Health Care • Medical Specialities
$84.88 ▼ -1.56
(-1.80%)
MKT CAP: $9.46B • VOL: 1.20M
52W L $68 52W H $92
HSIC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-27 | FY 2024
FILED 2024-12-28 | FY 2023
FILED 2023-12-30 |
|---|---|---|---|
| Revenue (Total Sales) | $13.18B | $12.67B | $12.34B |
| YoY Revenue Growth % | +4.0% | +2.7% | — |
| Gross Profit | $4.11B | $4.02B | — |
| Gross Margin % | 31.1% | 31.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $653.0M | $621.0M | $615.0M |
| Operating Margin % | 5.0% | 4.9% | 5.0% |
| Net Income (GAAP) | $419.0M | $398.0M | $436.0M |
| EBITDA (Normalized) | $1.13B | $1.08B | $1.06B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $712.0M | $848.0M | $500.0M |
| Capital Expenditures (CapEx) | $593.3M | $570.3M | $555.3M |
| Free Cash Flow (FCF) | $118.7M | $277.7M | -$55.3M |
| FCF Margin % | 0.9% | 2.2% | -0.4% |
| Return on Invested Capital (ROIC %) | 10.5% | 10.5% | 5.4% |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | $2.89B | $2.42B | $3.46B |
| Total Stockholders' Equity | $3.25B | $3.39B | $7.11B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HSIC.